Abstract
Significance Gaining insights into the efficacy of topical wound treatments for biofilm eradication is pivotal to enhancing wound management strategies. Despite numerous available agents claiming anti-biofilm properties, the substantiating evidence remains inconclusive. This study aimed to assess the immediate impact of topical wound treatments on wound biofilm and healing outcomes in acute and chronic ulcers.
Recent Advances We comprehensively searched PubMed, ClinicalTrials.gov, and Google Scholar. Additionally, eligible grey literature was incorporated. English-language randomized controlled trials, observational, cohort, and case-control studies targeting biofilm prevention, inhibition, or elimination across diverse wound types were included. Primary outcomes included biofilm presence and elimination, supplemented by secondary outcomes encompassing reduced wound size, complete closure, and diminished infection indicators. Bacterial load reduction and biofilm presence were also assessed.
Critical Issues Twenty-eight articles met the inclusion criteria. Various modalities were identified, including biofilm-visualization techniques like wound blotting and handheld autofluorescence imaging. A notable high bias risk was observed across all studies. Pooled analysis for the primary outcomes was infeasible due to limited eligible studies and data reporting challenges. The primary source of bias is the lack of consensus on objectively evaluating the biofilm. As for the secondary outcomes, the pooled analysis for complete wound closure (6 RCTs, yielding n=439) and presence of infection/inflammation (2 RCTs, yielding n=284) showed no significant difference, with log odds ratio (LOD) 0.03 (95% CI: – 1.02 – 1.09; τ2=1.09, SE: 1.10, Q=14.33, p=.014) and LOD – 0.95 (95% CI: – 3.54 – 1.64; τ2=2.32, Q=2.71, p=.10), respectively.
Future Direction Our findings suggest insufficient evidence to support anti-biofilm claims of topical modalities. Clinicians’ skill appears to play a pivotal role in biofilm elimination and wound healing enhancement, with potential optimization through visual-guided techniques like wound blotting and autofluorescence imaging. More rigorous clinical trials are warranted to ascertain the efficacy of these techniques.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
14. Abbreviations and Acronyms
- CI
- confidence interval
- DAC
- defensive antibacterial coating
- DFUs
- diabetic foot ulcers
- DMIST
- depth, maceration, inflection/inflammation, size, tissue of wound bed, tissue of wound edge, and tunneling/undermining
- LOD
- log odds ratio
- MeSH
- medical subject headings
- NaCl
- natrium chloride
- NPWT
- negative pressure wound therapy
- PFU
- plaque forming unit
- PHMB
- poly-hexamethylene biguanide
- PRISMA
- preferred reporting items for systematic reviews and meta-analyses
- RCTs
- randomized controlled trials
- SD
- standard deviation SE: standard error
- SOC
- standard of care
- TBSA
- total body surface area
